1 November 2023Read More
POA Pharma announces the launch of PKU Easy Microtabs Plus into the European Market
11 October 2023
POA Pharma, the privately-owned pharmaceutical sales and marketing company, has today announced the launch of PKU Easy Microtabs Plus in Germany and the Nordic region.
PKU Easy Microtabs Plus, which are specifically for individuals with Phenylketonuria (PKU), mark POA Pharma GmbH’s entry into the inborn metabolic disease (IMD) market.
The new PKU EASY Microtabs Plus product provides a ready-to-use phenylalanine-free protein substitute in micro tablet form, enriched with (‘plus’) vitamins and minerals, which replaces the requirement for a separate vitamin and minerals supplement.
Speaking on the company’s announcement, President and Managing Director of Galen, Dr Dennise Broderick said: “PKU Easy Microtabs Plus has been developed by our team of dedicated pharmaceutical and nutritional professionals with the goal of making a real contribution to making daily lives of those affected with PKU a little easier. The release of this new product is testament to our commitment of providing extraordinary service to the patients and healthcare professionals we work with every day.
“This launch is the first in a pipeline of products being developed for Northern Europe, which will build on solid-dose protein substitute expertise across a range of metabolic disorders including Homocystinuria (HCU), Urea Cycle Disorder (UCD) and Maple Syrup Urine Disease (MSUD) that will give patients greater choice and support.”
Following the initial launch in Germany and the Nordics, POA Pharma’s parent group Galen Limited is planning a phased rollout of the product across the UK, Europe, the USA and other global regions within the next 18 months.
Simon Lawrence, Commercial Director of Galen’s Nordic Region commented: “We have listened to the feedback from our dietitians around combining vitamins and minerals to our existing PKU EASY Microtabs. We have also carefully formulated the product, with a coating to improve palatability (minimal taste and smell) for the patient and an inner matrix which results in the slow-release of amino acids, helping individuals with PKU to manage their condition effectively while also providing all the essential nutrients to ensure a healthy, balanced lifestyle for our patients.
“We are excited to provide a more manageable product to the PKU Community through this improved formulation which will make a difference to patients.”
Notes to editors
About POA Pharma
Based in Copenhagen, POA Pharma Scandinavia AB, the parent company of POA Pharma GmbH, works every day to be of value to patients with inborn metabolic diseases (IMDs) and to their caregivers, offering POA products for Phenylketonuria (PKU) as well as for several other IMDs, which are currently available in the UK, Sweden, Norway, Denmark and Finland and the USA.
POA Pharma is part of Galen Limited, a privately owned company established in 1968, with global headquarters in Craigavon, Northern Ireland, and commercial operations based in the UK, Ireland, the Nordics, Europe, and the USA. With global partners in every continent, we are positioned to distribute products worldwide.
Galen Limited was founded in Northern Ireland by the late Sir Allen McClay (d. 2010), the revered philanthropist and entrepreneur, and has since become the proud founding member of the Almac Group.
With 7000+ employees and 18 facilities globally, the Almac Group is now owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health.
1 November 2023Read More
20 April 2023Read More
19 September 2022Read More